Literature DB >> 31420598

Chronic inflammation in multiple sclerosis - seeing what was always there.

Paul M Matthews1,2.   

Abstract

Activation of innate immune cells and other compartmentalized inflammatory cells in the brains and spinal cords of people with relapsing-remitting multiple sclerosis (MS) and progressive MS has been well described histopathologically. However, conventional clinical MRI is largely insensitive to this inflammatory activity. The past two decades have seen the introduction of quantitative dynamic MRI scanning with contrast agents that are sensitive to the reduction in blood-brain barrier integrity associated with inflammation and to the trafficking of inflammatory myeloid cells. New MRI imaging sequences provide improved contrast for better detection of grey matter lesions. Quantitative lesion volume measures and magnetic resonance susceptibility imaging are sensitive to the activity of macrophages in the rims of white matter lesions. PET and magnetic resonance spectroscopy methods can also be used to detect contributions from innate immune activation in the brain and spinal cord. Some of these advanced research imaging methods for visualization of chronic inflammation are practical for relatively routine clinical applications. Observations made with the use of these techniques suggest ways of stratifying patients with MS to improve their care. The imaging methods also provide new tools to support the development of therapies for chronic inflammation in MS.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31420598     DOI: 10.1038/s41582-019-0240-y

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  26 in total

Review 1.  Multispecific drugs herald a new era of biopharmaceutical innovation.

Authors:  Raymond J Deshaies
Journal:  Nature       Date:  2020-04-15       Impact factor: 49.962

Review 2.  Positron emission tomography in multiple sclerosis - straight to the target.

Authors:  Benedetta Bodini; Matteo Tonietto; Laura Airas; Bruno Stankoff
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

3.  Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.

Authors:  Milena Sales Pitombeira; Michel Koole; Kenia R Campanholo; Aline M Souza; Fábio L S Duran; Davi J Fontoura Solla; Maria F Mendes; Samira L Apóstolos Pereira; Carolina M Rimkus; Geraldo Filho Busatto; Dagoberto Callegaro; Carlos A Buchpiguel; Daniele de Paula Faria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-15       Impact factor: 10.057

Review 4.  Neuroinflammation and galectins: a key relationship in neurodegenerative diseases.

Authors:  Eleazar Ramírez Hernández; Beatriz Alanis Olvera; Daniela Carmona González; Oscar Guerrero Marín; Denisse Pantoja Mercado; Lucero Valencia Gil; Luis F Hernández-Zimbrón; José Luis Sánchez Salgado; I Daniel Limón; Edgar Zenteno
Journal:  Glycoconj J       Date:  2022-06-02       Impact factor: 3.009

Review 5.  Neurofilaments: neurobiological foundations for biomarker applications.

Authors:  Arie R Gafson; Nicolas R Barthélemy; Pascale Bomont; Roxana O Carare; Heather D Durham; Jean-Pierre Julien; Jens Kuhle; David Leppert; Ralph A Nixon; Roy O Weller; Henrik Zetterberg; Paul M Matthews
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

6.  Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS.

Authors:  Thanos Tsaktanis; Tobias Beyer; Lucy Nirschl; Mathias Linnerbauer; Verena Grummel; Mathias Bussas; Emily Tjon; Mark Mühlau; Thomas Korn; Bernhard Hemmer; Francisco J Quintana; Veit Rothhammer
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-24

7.  In Vivo Proton Exchange Rate (kex ) MRI for the Characterization of Multiple Sclerosis Lesions in Patients.

Authors:  Haiqi Ye; Mehran Shaghaghi; Qianlan Chen; Yan Zhang; Sarah E Lutz; Weiwei Chen; Kejia Cai
Journal:  J Magn Reson Imaging       Date:  2020-09-24       Impact factor: 4.813

Review 8.  Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.

Authors:  Jia Li; Meng Zheng; Olga Shimoni; William A Banks; Ashley I Bush; Jennifer R Gamble; Bingyang Shi
Journal:  Adv Sci (Weinh)       Date:  2021-06-03       Impact factor: 16.806

9.  Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging.

Authors:  Jin Zhang; Qianqian Du; Xiaowei Song; Shanshan Gao; Xuechao Pang; Yan Li; Ruiping Zhang; Zeper Abliz; Jiuming He
Journal:  Theranostics       Date:  2020-02-03       Impact factor: 11.556

Review 10.  White Matter and Neuroprotection in Alzheimer's Dementia.

Authors:  Luca Lorenzini; Mercedes Fernandez; Vito Antonio Baldassarro; Andrea Bighinati; Alessandro Giuliani; Laura Calzà; Luciana Giardino
Journal:  Molecules       Date:  2020-01-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.